Specialist biotech fund with a large exposure to US listed companies.
Prices as at 10 Aug 2022.
We don’t currently provide commentary on this fund.
Past performance is not an indication of future performance.
Capital at risk.
|Dividends paid||30 Apr, 31 Oct|
|Standard Initial Charge||0%|
|Initial Charge Via BestInvest||0%|
|Additional Bid/Offer Spread||0%|
|Annual Management Charge||0.75%|
|Ongoing Charges Figure||0.83%|
The fund’s investment universe consists of around 1000 public quoted biotech companies worldwide. These are filtered for such factors as ability to fund future operations and trading liquidity, reducing the universe to around 400-500 names which undergo qualitative analysis. Companies are assessed through contact with company management, attendance at conferences, consultation with industry experts and through consultation with other AXA Framlington fund managers. The manager targets companies with characteristics including: a strong product pipeline; quality management; robust clinical trial processes; market leading technologies. The process can also incorporate investment themes, such as the effects of the bird flu outbreak. Company sizes in the portfolio may be adjusted to reflect market conditions, with large, profitable companies favoured in more volatile environments.
Past performance is not a guide to future performance. View full risk warning